Steven Isaacman
Nanometics LLC
Affiliations
New York University
Technologies
Therapeutic
Indication
Basic Research
Clinical Research
Clinical Trials
Drug Discovery
Oncology
Orphan Diseases
Website
nanometicslab.comWe are developing an enzyme inhibitor with pico-‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-‐negative breast cancer.